Apellis Pharma raises $33 mln
Apellis Pharmaceuticals said Tuesday it has completed a $33 million private placement of its Series C Preferred Stock. The financing was led by Morningside Ventures and AJU IB Investment Co., Ltd. with Epidarex Ventures participating with follow-on funding. Appellis, of Crestwood, Kentucky, is a biotech company that applies immunotherapy to autoimmune disease.
2 December 2014•5 mins read
